OXFORD BIOMEDICA ORD 50P
-
GBX
(-)
- 15 min delayed data - London Stock Exchange
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | OXB |
| ISIN: | GB00BDFBVT43 |
OXFORD BIOMEDICA ORD 50P news, videos and press releases
For more news please use our advanced search feature.
OXFORD BIOMEDICA ORD 50P - More news...
OXFORD BIOMEDICA ORD 50P - More news...
- 09/18/2024 - 11:00 Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
- 09/02/2024 - 11:00 Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
- 08/27/2024 - 11:00 Oxford Biomedica to host a free webinar showcasing its AAV expertise
- 08/08/2024 - 11:00 Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
- 03/05/2024 - 12:00 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
- 01/29/2024 - 12:00 Oxford Biomedica completes acquisition of ABL Europe
- 01/23/2024 - 12:00 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
- 12/07/2023 - 12:00 Business Update
- 12/04/2023 - 12:04 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
- 09/20/2023 - 12:00 Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
- 09/20/2023 - 11:46 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
- 09/20/2023 - 11:41 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
- 09/07/2023 - 11:00 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
- 07/18/2023 - 07:00 Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
- 07/18/2023 - 07:00 Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
- 05/15/2023 - 11:00 Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
- 04/26/2023 - 11:00 Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
- 02/20/2023 - 12:00 Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
- 11/22/2022 - 12:00 Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
- 11/14/2022 - 12:00 Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
- 10/07/2022 - 11:00 Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
- 09/15/2022 - 11:00 OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
- 07/26/2022 - 11:00 Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
- 07/26/2022 - 11:00 Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
- 04/20/2022 - 11:00 Oxford Biomedica Preliminary Results
- 03/11/2022 - 12:00 Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
- 01/31/2022 - 21:13 Oxford Biomedica announces update to agreement with Sio Gene Therapies
- 01/28/2022 - 07:39 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
-
01/26/2022 - 08:21
Oxford Biomedica: Edison Open House Healthcare 2022
- 01/17/2022 - 07:00 John Dawson to retire from Oxford Biomedica
